Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2012
04/19/2012WO2012049639A1 Formulations of cetyl myristate and/or cetyl palmitate
04/19/2012WO2012049576A1 Crystalline sodium salt of cephalosporin antibiotic
04/19/2012WO2012049566A1 Combination therapy for use in treating diabetes
04/19/2012WO2012049555A1 Spirocyclic compounds as voltage-gated sodium channel modulators
04/19/2012WO2012049550A1 Liquid pharmaceutical composition for pain treatment and prevention
04/19/2012WO2012049545A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it
04/19/2012WO2012049544A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a hydrocortisone acetate as a corticosteroid, and clotrimazole as an antifungal agent, and a process to make it
04/19/2012WO2012049543A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
04/19/2012WO2012049542A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, mometasone as a corticosteroid and clotrimazol as antifungal agent, and a process to make it
04/19/2012WO2012049541A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
04/19/2012WO2012049540A1 A medicinal fusidic acid cream made using sodium fusidate, a corticosteroid, and an antifungal agent, and incorporating a biopolymer, and a process to make it
04/19/2012WO2012049539A1 A medicinal fusidic acid cream made using sodium fusidate, a corticosteroid, and an antifungal agent, and incorporating a biopolymer, and a process to make it
04/19/2012WO2012049534A1 Food supplement
04/19/2012WO2012049444A1 Pharmaceutical composition
04/19/2012WO2012049440A1 Treatment of cancer/inhibition of metastasis
04/19/2012WO2012049439A1 Treatment of cancer/inhibition of metastasis
04/19/2012WO2012049346A1 Hypocholesterolemic, anti-inflammatory and antiepileptic neuroprotective compound
04/19/2012WO2012049327A2 Pesticidal mixtures
04/19/2012WO2012049277A1 Cxcr4 receptor antagonists
04/19/2012WO2012049253A1 Curcuminoid solid dispersion formulation
04/19/2012WO2012049227A2 Novel omega-3 and omega-6 fatty acid compositions and uses thereof
04/19/2012WO2012049222A2 Novel omega-3 and omega-6 fatty acid compositions and uses thereof
04/19/2012WO2012049190A1 N-pyridin-3-yl or n-pyrazin-2-yl carboxamides
04/19/2012WO2012049161A1 3 -amino- pyrazole derivatives useful against tuberculosis
04/19/2012WO2012049159A1 Composition for treating cancer by the controlled release of an active substance
04/19/2012WO2012049153A1 Process for manufacturing dihydropteridinones and intermediates thereof
04/19/2012WO2012049112A1 Egfr aptamer inhibitor for use in therapy and diagnosis
04/19/2012WO2012049108A1 Axl receptor tyrosine kinase aptamer inhibitor for use in therapy
04/19/2012WO2012048894A1 Hybrid compounds of 4- and 8-aminoquinolines for the prophylactic and therapeutic treatment of malaria and other parasitic diseases
04/19/2012WO2012048871A1 Memantine for improving cognitive performance in subjects
04/19/2012WO2012048775A1 Pyrrolidinones as metap2 inhibitors
04/19/2012WO2012048710A1 Combinations of serotonin receptor agonists for treatment of movement disorders
04/19/2012WO2012048522A1 Fructosylated puerarin, and preparation method therefor and use thereof
04/19/2012WO2012048470A1 Small molecular ribonucleic acid complexes from mammals
04/19/2012WO2012048455A1 Transdermal absorption patch of antiviral drug and its preparation method
04/19/2012WO2012048421A1 Hepatitis c inhibitor compounds
04/19/2012WO2012048417A1 Inhibitors of p75 receptor and their uses
04/19/2012WO2012048414A1 A method of regulating plasma lipoproteins
04/19/2012WO2012048411A1 Plk-4 inhibitors and method of treating cancer with same
04/19/2012WO2012027727A3 Lipomacrocycles and uses thereof
04/19/2012WO2012027326A9 Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
04/19/2012WO2012024519A3 Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
04/19/2012WO2012022796A3 Novel combinations
04/19/2012WO2012018635A3 Arylsulfonamide derivatives, compositions, and methods of use
04/19/2012WO2012017385A3 Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and process for obtaining them
04/19/2012WO2012016889A3 Dry powder formulation comprising a phosphodiesterase inhibitor
04/19/2012WO2012015937A9 Parp1 targeted therapy
04/19/2012WO2012015168A3 Pharmaceutical composition comprising rosuvastatin or a pharmaceutically acceptable salt thereof
04/19/2012WO2012012798A3 Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases
04/19/2012WO2012009288A9 Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
04/19/2012WO2012009262A3 Diclofenac salt of tramadol
04/19/2012WO2012009171A3 Compositions and methods of treatment of corneal endothelium disorders
04/19/2012WO2012006315A3 Methods of immune modulation
04/19/2012WO2011163636A3 Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
04/19/2012WO2011163319A3 Activation of amp-protein activated kinase by oxaloacetate compounds
04/19/2012WO2011163308A3 Compositions and methods for preventing and treating organ injury and/or dysfunction
04/19/2012WO2011161501A3 Solid compositions in form of powders or granulates for the oral administration of active ingredients and method for obtaining them
04/19/2012WO2011159871A3 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
04/19/2012WO2011159839A3 Thioacetate compounds, compositions and methods of use
04/19/2012WO2011159781A3 Bitter taste modulators
04/19/2012WO2011159771A3 Compositions and methods for treating cancer
04/19/2012WO2011159067A3 Thiazole derivatives as sglt2 inhibitors and pharmaceutical composition comprising same
04/19/2012WO2011158176A3 Gold complexes for use in the treatment of cancer
04/19/2012WO2011156812A3 Intravaginal administration of misoprostol
04/19/2012WO2011156780A3 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
04/19/2012WO2011156775A3 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
04/19/2012WO2011156646A3 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
04/19/2012WO2011156518A3 Estrogen receptor modulators and uses thereof
04/19/2012WO2011156405A3 Oral spray formulations and methods for administration of sildenafil
04/19/2012WO2011156245A3 Positive allosteric modulators of mglur2
04/19/2012WO2011155803A3 Novel compound having hearing protection effects
04/19/2012WO2011153502A3 Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using them
04/19/2012WO2011153334A3 Bioadhesive compositions for epithelial drug delivery
04/19/2012WO2011153331A3 Optical sensor conjugates for detecting reactive oxygen and/or reactive nitrogen species in vivo
04/19/2012WO2011153192A3 Cytochrome p450 inhibitors and uses thereof
04/19/2012WO2011153157A3 Benzoquinolone inhibitors of vmat2
04/19/2012WO2011151395A3 Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
04/19/2012WO2011150229A3 Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity
04/19/2012WO2011150156A3 Heteroaryl compounds and methods of use thereof
04/19/2012WO2011150094A3 Tumor suppression compositions
04/19/2012WO2011149881A3 Methods for the treatment and prevention of inflammatory diseases
04/19/2012WO2011149766A3 Lipid-tailored pharmaceutical agents
04/19/2012WO2011149529A3 Cell-based preparations for wound management
04/19/2012WO2011149288A3 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
04/19/2012WO2011149206A3 Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same
04/19/2012WO2011146922A3 Materials and methods for treatment of inflammation
04/19/2012WO2011139794A3 A composition for skin sanitization and protection and method of its use
04/19/2012WO2011138797A3 Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
04/19/2012WO2011133963A3 Tyrosine-based prodrugs of antiviral agents
04/19/2012WO2011133858A3 Compositions, methods of use, and methods of treatment
04/19/2012WO2011130692A3 Androgen induced oxidative stress inhibitors
04/19/2012WO2011129936A4 Compositions and methods for the prevention and treatment of cancer
04/19/2012WO2011129765A9 Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
04/19/2012WO2011128783A3 Stable liquid oily ready-to-use formulations, preparation thereof and use thereof
04/19/2012WO2011127337A3 Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
04/19/2012WO2011127202A3 Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
04/19/2012WO2011127070A3 IRE-1α INHIBITORS
04/19/2012WO2011126821A3 Indolyl or indolinyl hydroxamate compounds
04/19/2012WO2011126544A3 Thymoquinone analogs for the treatment of pancreatic cancer
04/19/2012WO2011123745A3 Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3